elranatamab will boost the level or outcome of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Elranatamab causes cytokine launch syndrome (CRS) that will suppress exercise of CYP enzymes, resulting in amplified publicity of CYP substrates.isavuconazonium sulfate will enhance the stage or effect of